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MaOBJECTIVES This study sought to evaluate the prognostic usefulness of visual and quantitative perfusion
cardiac magnetic resonance (CMR) ischemic burden in an unselected group of patients and to assess the validity of
consensus-based ischemic burden thresholds extrapolated from nuclear studies.
BACKGROUND There are limited data on the prognostic value of assessing myocardial ischemic burden by CMR, and
there are none using quantitative perfusion analysis.
METHODS Patients with suspected coronary artery disease referred for adenosine-stress perfusion CMR were
included (n ¼ 395; 70% male; age 58  13 years). The primary endpoint was a composite of cardiovascular death,
nonfatal myocardial infarction, aborted sudden death, and revascularization after 90 days. Perfusion scans were
assessed visually and with quantitative analysis. Cross-validated Cox regression analysis and net reclassiﬁcation
improvement were used to assess the incremental prognostic value of visual or quantitative perfusion analysis over a
baseline clinical model, initially as continuous covariates, then using accepted thresholds of $2 segments or $10%
myocardium.
RESULTS After a median 460 days (interquartile range: 190 to 869 days) follow-up, 52 patients reached the primary
endpoint. At 2 years, the addition of ischemic burden was found to increase prognostic value over a baseline model of
age, sex, and late gadolinium enhancement (baseline model area under the curve [AUC]: 0.75; visual AUC: 0.84;
quantitative AUC: 0.85). Dichotomized quantitative ischemic burden performed better than visual assessment (net
reclassiﬁcation improvement 0.043 vs. 0.003 against baseline model).
CONCLUSIONS This study was the ﬁrst to address the prognostic beneﬁt of quantitative analysis of perfusion CMR and
to support the use of consensus-based ischemic burden thresholds by perfusion CMR for prognostic evaluation of
patients with suspected coronary artery disease. Quantitative analysis provided incremental prognostic value to visual
assessment and established risk factors, potentially representing an important step forward in the translation of
quantitative CMR perfusion analysis to the clinical setting. (J Am Coll Cardiol Img 2017;-:-–-) © 2017 The Authors.
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ABBR EV I A T I ON S
AND ACRONYMS
AHA = American Heart
Association
CABG = coronary artery bypass
grafting
CMR = cardiac magnetic
resonance
IQR = interquartile range
LGE = late gadolinium
enhancement
MBF = myocardial blood ﬂow
MPR = myocardial perfusion
reserve
PCI = percutaneous coronary
intervention
PET = positron emission
computed tomography
ROI = region of interest
SCD = sudden cardiac death
SPECT = single-photon
emission computed
tomography
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2I n recent years, stress perfusion cardiacmagnetic resonance (CMR) has becomeone of the methods of choice for the
diagnosis of coronary artery disease based
on high diagnostic accuracy, lack of ionizing
radiation, and the ability to simultaneously
assess cardiac function, myocardial perfu-
sion, and viability (1–3). In the clinical
setting, perfusion CMR is assessed qualita-
tively with visual analysis (4). There are
data that show that ischemia detection by vi-
sual assessment performs similarly or is at
least noninferior to other noninvasive mo-
dalities such as positron emission tomogra-
phy (PET) or single-photon emission
computed tomography (SPECT) (5–7).
There is a growing body of evidence that
shows that the mere presence of ischemia is
of prognostic value (8–12); however, in recent
years, the burden of ischemia has become an
important focus (13,14). SPECT allows quan-
tiﬁcation of relative ischemic burden in terms
of percentage of ischemic myocardium, andaccepted thresholds have been shown to be of prog-
nostic value in large nuclear data sets (13,15). The
thresholds of ischemic burden used in SPECT have
been extrapolated to CMR (16,17); however, evidence
regarding the validity of these thresholds for CMR is
lacking.
CMR perfusion quantiﬁcation has been shown to be
feasible and has been validated against invasive and
noninvasive modalities, including fractional ﬂow
reserve (18) and PET (19). Although both visual and
quantitative analysis can provide data on ischemic
burden, there are data that suggest the diagnostic
superiority of quantitative CMR perfusion analysis,
speciﬁcally in the setting of multivessel coronary
disease (20). A direct comparison between visual and
quantitative perfusion CMR in terms of prognostic
beneﬁt has yet to be performed.
The main aim of this study was to assess the
prognostic value of quantitative CMR perfusion
analysis. Furthermore, we aimed to investigate the
validity of accepted consensus-based thresholds for
ischemic burden in the setting of adenosine stress
perfusion CMR.
METHODS
STUDY DESIGN. Patients with suspected coronary ar-
tery disease referred on a clinical basis to King’s Col-
lege London CMR Service at St Thomas’ Hospital
(Guy’s and St Thomas’ NHS Trust) between January
2009 and January 2015 were considered forenrollment. Consecutive patients who underwent a
clinical CMR scan that included assessment of cardiac
function, ischemia testing with high-resolution dual-
bolus adenosine stress, and resting perfusion imaging,
followed by late gadolinium enhancement (LGE) im-
aging were included. Patients in whom regadenoson
was used were excluded because the long half-life of
the drug has the potential to result in the acquisition of
resting perfusion images with a degree of residual
hyperemia, which results in the underestimation of
myocardial perfusion reserve (MPR) (21,22).
The study was conducted in accordance with the
Declaration of Helsinki (2000) and was approved by
the National Research Ethics Service. All patients
provided written informed consent.
STUDY ENDPOINT AND PATIENT FOLLOW-UP. The
start of follow-up was deﬁned as the date of the CMR
scan. The primary endpoint was a composite of car-
diovascular death (death due to myocardial infarc-
tion, heart failure, or ventricular arrhythmia),
nonfatal myocardial infarction (acute coronary syn-
drome with associated electrocardiographic changes
and elevation of serum biomarkers of myocardial
necrosis to >99th percentile of the assay upper limit
of normal [23]), aborted sudden cardiac death (SCD)
(documented ventricular ﬁbrillation or sustained
ventricular tachycardia with hemodynamic compro-
mise requiring deﬁbrillation or cardioversion not
associated with acute myocardial infarction), and late
revascularization (percutaneous coronary interven-
tion [PCI] or coronary artery bypass grafting [CABG]
>90 days after the start of follow-up). To avoid the
potential effect of a positive CMR result leading to
early revascularization, we excluded procedures
within 90 days of the CMR scan from the deﬁnition of
the endpoint revascularization (24). Patients who did
not experience events were censored at the point of
last follow-up. When patients experienced >1 event,
only the ﬁrst event was considered.
Follow-up was performed through interrogation of
electronic patient records and patient notes. All
events were adjudicated by consensus of 3 physicians
blinded to CMR data. Mortality and cause of death
were obtained from the Ofﬁce for National Statistics
and through review of medical records, death certif-
icates, and post-mortem data where available.
IMAGE ACQUISITION. Patients were asked to refrain
from nicotine and caffeine-containing foods and
beverages for 24 h before the scan. Standard 2-, 3-,
and 4-chamber cine images were acquired during
breath hold. Contiguous short-axis slices were ac-
quired from the base to the apex for calculation of left
ventricular volumes, function, and mass. Following
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34 min of adenosine (140 mg/kg/min, increased to
210 mg/kg/min if there was an inadequate response,
which was considered an increase in heart rate
at peak stress of <10% above baseline [25]), stress
perfusion data were acquired in 3 short-axis slices
with a saturation-recovery k-t sensitivity encoding
accelerated gradient-echo method (26), which
covered 16 of the standard myocardial segments
(segment 17 was excluded).
A dual-bolus contrast agent scheme was used to
correct for signal saturation of the arterial input
function as previously described (27). In brief, 0.0075
mmol/kg gadobutrol (Gadovist, Bayer, Berlin, Ger-
many) was administered as a pre-bolus at peak stress
with imaging of the arterial input function. First-pass
perfusion data were then acquired after the injection
of 0.075 mmol/kg gadobutrol at 4 ml/s, followed by a
20-ml saline. Resting perfusion imaging was per-
formed after a minimum of 15 min following the
stress acquisition before acquisition of LGE imaging
according to Society for Cardiovascular Magnetic
Resonance (SCMR) guidelines (28). LGE imaging was
performed after a further dose of contrast agent, to a
total dose of 0.2 mmol/kg.
IMAGE ANALYSIS. Ventricular volumes, atrial size,
and left ventricular mass were calculated and
normalized to body surface area (CVI42, v5.1.1, Circle
Cardiovascular Imaging, Calgary, Ontario, Canada).
Segmental mass was measured in end-diastole and
expressed as percentage of total myocardial mass.
Visual assessment was performed using stress and
resting perfusion, and LGE images by the consensus
of 2 SCMR level III accredited physicians using the
standard 16-segment American Heart Association
(AHA) model and standardized reporting criteria.
Scans were reported visually on a clinical basis;
therefore, baseline clinical data were available to the
observers who performed visual assessment.
A perfusion abnormality was deﬁned visually ac-
cording to the criteria previously described in the MR-
INFORM (MR Perfusion Imaging to GuideManagement
of Patients With Stable Coronary Artery Disease) trial
(17), as a delayed wash-in of contrast persisting for $5
dynamics in $1 AHA segments compared with normal
remote myocardium. Each AHA segment was sub-
divided into an endocardial and epicardial half, which
resulted in a total of 32 segments to allowmore accurate
calculation of ischemic burden. Segments inwhichLGE
was present were excluded from ischemia assessment.
Surface coil intensity correction was performed
before quantiﬁcation using pre-contrast imaging data
(29). Time signal-intensity curves were extracted us-
ing commercially available software (CVI42).Quantitative analysis was performed blinded to
baseline clinical data.
Quantitative perfusion analysis was performed by
Fermi-constrained deconvolution according to the
previously described methods (30,31), in which time-
signal intensity curves for the tissue impulse
response function, h(t), were ﬁtted to the Fermi
function using a Marquardt-Levenberg nonlinear
least-squares algorithm according to the following
analytical expression:
hðtÞ ¼ R

1
eðts0sdÞk þ 1

uðt  sdÞ
by letting k, R, and s0 vary and keeping sd ﬁxed. In the
preceding equation, u(t  sd) is the unit step function.
The sd accounts for the delay time between the
appearance of the signal in the left ventricular blood
pool and myocardial region of interest (ROI); s0
characterizes the width of the shoulder of the Fermi
function during which little or no contrast agent had
left the ROI. R is the index of contrast agent inﬂux
parameter, and k represents the decay rate of h(t) due
to contrast agent washout. Using the preceding
equation, myocardial blood ﬂow (MBF) estimates are
calculated as h(t) at t ¼ 0. MPR was calculated as the
ratio between stress and resting MBF estimates (32).
Ischemia was deﬁned as segments with MPR <1.5,
according to previously validated criteria (18).
STATISTICAL METHODS. Statistical analysis was
performed by 2 of the authors (S.S. and T.I.). Data for
categorical variables are presented as frequencies and
percentages. Data for continuous variables are pre-
sented as mean  SD or as median and interquartile
range (IQR) depending on normality. The study
cohort was stratiﬁed according to the presence or
absence of events during follow-up.
Differences between categorical variables were
evaluated using Fisher exact test. Comparisons be-
tween continuous variables were performed with
the independent samples Student t test or using the
Wilcoxon rank-sum test as appropriate. Two-tailed
p values <0.05 were considered signiﬁcant.
Survival risk classiﬁers were built using penalized
Cox proportional hazards models with a L1-(Lasso)
penalty. Double-loop, cross-validation with 500 re-
starts was used to obtain robust unbiased estimates of
predictive strength as outlined by Simon et al. (33). A
baseline model was built containing established
prognostic variables (age, sex, and LGE) as unpenal-
ized independent variables. Left ventricular ejection
fraction, revascularization within 90 days, and pre-
scan revascularization (34) also entered the baseline
model and were subject to penalization. None of
TABLE 1 Baseline Clinical and CMR Characteristics
No Event
(n ¼ 343; 86.8%)
Event
(n ¼ 52; 13.2%)
Total
(N ¼ 395; 100%)
p
Value
Age, yrs 57.6  13.2 63.3  11.8 58.3  13.1 0.019
Male 226 (65.9) 51 (98.1) 277 (70.1) <0.001
Body mass index, kg/m2 1.95  0.23 2.00  0.20 1.96  0.23 0.612
Risk factors
Diabetes mellitus 66 (19.2) 12 (23.5) 78 (19.7) 0.575
Hypertension 201 (58.6) 34 (66.7) 235 (59.5) 0.368
Current smoker 63 (18.4) 10 (19.2) 73 (18.5) 0.849
Ex-smoker 31 (9.0) 4 (7.7) 35 (8.9) 1.000
Hypercholesterolemia 180 (52.5) 36 (72) 216 (54.7) 0.025
Previous PCI/CABG 101 (29.2) 34 (65.4) 135 (34.2) <0.001
PCI/CABG within 90 days 36 (10.5) 4 (7.7) 40 (10.1) 0.804
Atrial ﬁbrillation 36 (10.5) 10 (19.2) 46 (11.6) 0.100
CMR characteristics
LVEDV, ml 152 (130–183) 156 (125–195) 153 (129–183) 0.462
Indexed LVEDV, ml/m2 78 (67–91) 79 (65–96) 79 (67–91) 0.790
LVESV, ml 60 (47–82) 65 (41–97) 60 (46–84) 0.223
Indexed LVESV, ml/m2 30 (24–40) 32 (22–47) 31 (24–41) 0.374
LVEF, % 60 (53–66) 59 (44–67) 60 (52–66) 0.121
LV mass, g 107 (88–134) 115 (97–134) 109 (90–134) 0.086
Indexed LV mass, g/m2 55 (46–66) 60 (50–67) 56 (47–56) 0.075
RVEDV, ml 149 (126–174) 143 (114–170) 147 (124–174) 0.185
Indexed RVEDV, ml/m2 75 (64–87) 73 (60–88) 31 (23–38) 0.178
RVESV, ml 62 (44–77) 57 (46–78) 61 (44–77) 0.671
Indexed RVESV, ml/m2 31 (23–39) 31 (22–38) 31 (23–38) 0.610
LA size, cm2 23 (20–26) 22 (18–27) 23 (19–26) 0.944
RA size, cm2 20 (17–23) 21 (18–24) 20 (17–23) 0.464
Resting heart rate, beats/min 71.8  14.2 68.7  13.5 70.8  14.0 0.182
Stress heart rate, beats/min 96.8  17.4 90.9  16.1 95.6  17.6 0.042
Rest systolic BP, mm Hg 137.9  22.7 137.4  22.2 137.9  22.4 0.859
Rest diastolic BP, mm Hg 79.3  12.5 74.9  10.9 78.6  12.5 0.097
Stress systolic BP, mm Hg 132.9  20.6 131.8  19.8 132.8  20.4 0.652
Stress diastolic BP, mm Hg 74.5  12.5 74.5  9.8 74.5  12.2 0.763
Visual ischemic burden, % 14.7  29.2
0 (0.0–12.5)
29.6  28.2
25 (0–50)
17.2  29.7
0 (0–25)
<0.001
MPR ischemic burden, % 6.09  14.6
0 (0.0–4.9)
25.1  22.0
23.4 (1.3–39.0)
8.35  16.7
0 (0.0–8.5)
<0.001
Values are mean  SD, n (%), or median (interquartile range).
BP ¼ blood pressure; CABG ¼ coronary artery bypass grafting; CMR ¼ cardiac magnetic resonance; LA ¼ left
atrial; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; LVEDV ¼ left ventricular end-diastolic
volume; LVESV ¼ left ventricular end-systolic volume; MPR ¼ myocardial perfusion reserve; PCI ¼ percuta-
neous coronary intervention; RA ¼ right atrial; RVEDV ¼ right ventricular end-diastolic volume; RVESV ¼ right
ventricular end-systolic volume.
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4these penalized variables were found to provide
predictive information, and therefore, were not
retained in the ﬁnal model speciﬁcation. The baseline
model was then extended to include visual ischemic
burden or MPR ischemic burden. The predictive per-
formance of the resulting enriched models was eval-
uated by 10-fold cross-validation with 500 restarts
(33). Survival probabilities were derived for each pa-
tient for the 2-year time point. The 2-year time point
was chosen on the basis of $75% of the cohort having
a follow-up of 869 days (2.4 years). Cross-validated,
receiver-operating characteristic curves were createdfor each model at 2 years, and the associated cross-
validated area under the curve was determined (35).
Patients were classiﬁed into 3 categories: low (<1%),
intermediate (1% to 3%), and high (>3%) risk as
speciﬁed by current American College of Cardiology
guidelines (3). Cross-validated categorical net reclas-
siﬁcation improvement and integrated discrimination
improvement reclassiﬁcation metrics were then
computed for the 2 perfusion models in relation to the
baseline model (36).
After establishing the independent predictive
value of each measure of perfusion as a continuous
covariate, the perfusion measures were dichotomized
using a threshold of $2 segments for visual ischemia
and $10% for ischemic MPR (16). Model performance
was reassessed as previously described using cross-
validated Cox regression and reclassiﬁcation metrics
for the 2-year time point. Kaplan-Meier-curves were
produced for time to the composite endpoint to
visualize the discriminative power of LGE and
perfusion measurements. All statistical analysis was
performed with R version 3.3.0 (R Core Team, R
Foundation for Statistical Computing, Vienna,
Austria).
RESULTS
A total of 434 patients met the inclusion criteria: 24
(5.5%) were lost to follow-up, and 15 (3.5%) were
excluded due to poor image quality. The baseline
clinical and CMR characteristics of the ﬁnal cohort of
395 patients stratiﬁed by event status are listed in
Table 1. Patients tended to be middle-aged (58  13
years) and mostly men (70%); most had hypertension
(59.5%) or hypercholesterolemia (54.7%), and
approximately 1 in 5 had diabetes (19.7%). Approxi-
mately one-third of the patients had had previous
revascularization either by PCI or CABG. Approxi-
mately one-third (34.9%) of the patients had
stress-induced perfusion abnormalities on visual
assessment, and 35.4% were positive for LGE. In total,
40 patients underwent revascularization within 90
days (n ¼ 7 CABG, n ¼ 33 PCI, at a median of 30 and 36
days, respectively, post-CMR), and these events were
excluded from subsequent analysis.
The median follow-up was 460 days (IQR: 190 to
869 days). Overall, 52 patients met the primary
endpoint: 39 patients underwent revascularization
after 90 days (n ¼ 23 elective PCI for stable angina, at
a median 196 days [IQR: 135 to 240 days] after CMR;
n ¼ 5 unplanned PCI for unstable angina, median 220
days [IQR: 140 to 704 days] after CMR; 10 patients
underwent elective CABG, median 188 days [IQR: 148
to 282 days] after CMR; and 1 patient had unplanned
FIGURE 1 ROC Curves for Visual and MPR Ischemic Burden
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Receiver-operator characteristic (ROC) curves for 2-year outcome for the baseline cross-validated Cox regression model and for the extended
models, including visual and ischemic burden (myocardial perfusion reserve [MPR]) as a (A) continuous or (B) dichotomized covariate.
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5CABG for unstable angina, 190 days after CMR).
Other events consisted of nonfatal myocardial
infarction in 7 cases, median 896 days (IQR: 56 to
1,160 days) after CMR (leading to unplanned revas-
cularization in 3 subjects), 4 cardiovascular deaths at
508 days after CMR (IQR: 186 to 856 days) and 2
aborted sudden cardiac deaths (SCDs) at 16 and 443
days after CMR.
The baseline cross-validated Cox regression model
found the linear predictors to be age, sex, and LGE as
follows:
w0:025$ageþ 2:993$sexþ 0:616$LGE
The addition of visual ischemic burden as a
continuous covariate yielded a linear predictor of:
w0:028$ageþ 3:108$sexþ 0:563$LGE
þ 1:423$visualischemic burden
The corresponding model for MPR ischemic burden
as a continuous covariate was:
w0:02$ageþ 2:722$sexþ 0:678$LGE
þ 2:490$MPRischemic burden
Figure 1A illustrates the receiver-operating charac-
teristic curves for 2-year outcome for these 3 models.The addition to the baseline model of dichoto-
mized visual ischemic burden using a threshold of $2
segments yielded a model of:
w0:019$ageþ 2:949$sexþ 0:486$LGE
þ 1:374$visual2 segments
The corresponding model for dichotomized MPR
ischemic burden using a threshold of $10% ischemic
myocardium was:
w0:016$ageþ 2:486$sex þ 0:497$LGEþ 1:761$MPR10%
Ischemia assessment by visual or quantitative
analysis signiﬁcantly improved predictive perfor-
mance in comparison to the baseline model alone.
When established clinical thresholds were used, there
were further signiﬁcant improvements in model per-
formance (Figure 1B), which translated into a signiﬁ-
cant improvement in risk reclassiﬁcation (Figure 2).
Kaplan-Meier curves illustrating survival in patients
stratiﬁed according to LGE, and dichotomized visual
and quantitative perfusion ﬁndings are shown in
Figure 3.
On further analysis of the concordance of results
obtained from visual and quantitative analysis, the
incidence of primary events was noted to be highest
FIGURE 2 Cross-Validated Categorical NRI and IDI Reclassiﬁcation for the Baseline
and the Perfusion Models
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6in the context of concordant positive tests (53.9% of
the total events). The lowest event rate was observed
in patients with negative results for both tests (9.6%).
In cases of disagreement, we observed a higher
number of patients meeting the primary endpoint
when classiﬁed as positive on quantitative analysis
(23.1%) compared with those who were positive only
on visual assessment (13.5%).
DISCUSSION
The present study represents the ﬁrst to address the
prognostic beneﬁt of quantitative analysis of stress
perfusion CMR. A quantitative approach was previ-
ously shown to signiﬁcantly improve diagnostic per-
formance over visual assessment speciﬁcally in the
setting ofmultivessel coronary artery disease (20). Our
data demonstrated that a quantitative approach was
also superior to a visual assessment in an unselected
group of patients from a prognostic perspective.
Moreover, our data demonstrated the incremental
prognostic value of ischemic burdenmeasurements by
visual or quantitative assessment over established risk
factors, including LGE, which highlighted the strength
of CMR as a multiparametric technique.
In this study, both visual and quantitative analysis
were performed in a high-volume tertiary center and
by experts. It was a signiﬁcant ﬁnding that the semi-
automated quantitative analysis performed similarly,
if not slightly better, than visual assessmentof Signiﬁcant Visual or Quantitative Ischemic Burden and LGE
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7performed by expert readers. This is of increasing
relevance because recent technical advances in image
reconstruction and analysis techniques are likely to
permit robust full automation of quantitative analysis
in the coming years (37,38). The ﬁndings of this study
have important implications for facilitating more
widespread adoption of stress perfusion CMR by less
experienced readers and allowing the prognostic
value of perfusion quantiﬁcation to be realized.
It was encouraging that there were only a small
number of nonanalyzable cases (3.5%), mainly due to
respiratory motion, which is known to be a limitation
of the high-resolution k-t accelerated techniques used
in this study (39). The advent of novel motion correc-
tion techniques will likely ameliorate this further (40).
We found that the consensus-based threshold
of $10% ischemic myocardium or $2 abnormal seg-
ments could be validly extrapolated from nuclear
medicine to CMR (16). The use of these thresholds not
only improvedmodel predictive performance, but also
translated into signiﬁcant reclassiﬁcation of patient
risk using established risk categories. This was a reas-
suring ﬁnding because important studies such as MR-
INFORM and the ISCHEMIA (International Study of
Comparative Health Effectiveness with Medical and
Invasive Approaches) trial used these criteria (16,17).
In the present study, abnormal perfusion was
deﬁned by an MPR <1.5. This threshold was previ-
ously validated against fractional ﬂow reserve (18)
and was similar to the optimal threshold found in
some PET studies in patients with angina who require
revascularization (41).
STUDY LIMITATIONS. This was a single-center study,
although it took place at a tertiary hospital with a
high-volume CMR service. This likely introduced a
selection bias despite the enrollment of consecutive
patients. However, a single-center design allowed
standardization of pharmacological stress protocols
and acquisition methods. A dual-bolus approach was
used, justiﬁed by the need to minimize signal satu-
ration effects in the arterial input function. Although
the relative complexity of this approach makes it
more difﬁcult for less experienced centers to adopt,
the emergence of dual-sequence acquisition schemes
and other advances might render this less of a barrier
in the future (42).
Mirroring previous clinical studies, in which visual
CMR results could have inﬂuenced revascularization
decisions, we excluded early revascularization events
(within 90 days) from the primary composite endpoint
(24). All scan reports were issued within 5 days, with a
median time between scan to early revascularization
of 36 days. As an additional precaution, to assess anypotential bias this might have had on our results, we
forced early revascularization as a covariate in our
models and found that it had no impact on our ﬁnd-
ings. On this basis, we believed that the cutoff of 90
days appeared to be reasonable in our cohort for
minimizing the inﬂuence of visual CMR results on
revascularization decisions. Furthermore, we also
proposed if there were any bias present, this would
have favored a visual analysis approach because this
was used for clinical decision making. We recognize
that we could not fully exclude the possibility that the
impact of ischemia might have been underestimated
as a result of prompt revascularization.
The presence of severe ischemia, deﬁned as
vasodilator-induced systolic dysfunction by CMR,
was previously shown to predict poor prognosis in a
large series of patients and to identify a subgroup of
patients who beneﬁtted most from revascularization
(43,44). A comprehensive evaluation of the ischemic
cascade, including induced-systolic dysfunction, was
not performed in this study.
Finally, this study focused solely on perfusion CMR
and used visual assessment as the clinical reference
standard. CMR perfusion was not directly compared
with other noninvasive modalities. PET remains the
noninvasive reference method for quantitative perfu-
sionmeasurements.However, it isnotwidelyavailable,
is costly, and uses ionizing radiation. SPECT is more
widely used, but it also uses ionizing radiation and has
lower spatial resolution than CMR. Visual and quanti-
tative CMRanalysiswere shown to perform similarly or
better than these modalities in other studies, but a
direct comparison was not possible in this study (7,19).
CONCLUSIONS
This study supported the use of the current consensus-
based prognostic ischemic burden thresholds for
perfusion CMR. Quantitative perfusion analysis per-
formed similar to, or when using a threshold-based
approach, better than visual assessment. This ﬁnding
represents a potentially important step forward in the
goal of translating quantitative CMR perfusion anal-
ysis to the clinical setting. Our data support the need
for larger, multicenter prospective randomized-
controlled studies to further explore the prognostic
implications of quantitative CMR perfusion analysis.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
evaluation of ischemic burden by stress perfusion CMR
using either visual or quantitative assessment provides
incremental prognostic value over established risk fac-
tors, including scar on late gadolinium enhancement im-
aging. The consensus-based threshold of $10% ischemic
myocardium or $2 abnormal segments in widespread
clinical use can be validly extrapolated from nuclear
medicine to stress perfusion CMR. Quantitative analysis of
perfusion CMR provides improved predictive power of
events and reclassiﬁcation of patients compared with
visual analysis.
TRANSLATIONAL OUTLOOK: This represents an
important step in supporting the translation of quantita-
tive analysis of perfusion CMR to the clinical setting.
Randomized trials are needed to validate these observa-
tional data and conﬁrm the prognostic impact of a
quantitative CMR-based strategy for guiding revasculari-
zation decisions.
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